{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:42:47Z","timestamp":1792813367312,"version":"4.5.0"},"reference-count":25,"publisher":"Japanese Circulation Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2026,10,23]]},"DOI":"10.1253\/circj.cj-26-0576","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T22:11:33Z","timestamp":1790633493000},"page":"1620-1628","source":"Crossref","is-referenced-by-count":1,"title":["Stage-Specific Cost-Effectiveness of Early vs. Delayed Tafamidis for Transthyretin Amyloid Cardiomyopathy in Japan"],"prefix":"10.1253","volume":"90","author":[{"given":"Yasufumi","family":"Nagata","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Nabeshima","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University of Saga, School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Kitano","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Mie University Hospital, School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Tabata General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaharu","family":"Kataoka","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Occupational and Environmental Health, School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"publisher","unstructured":"1. Lane T, Fontana M, Martinez-Naharro A, Quarta CC, Whelan CJ, Petrie A, et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. <i>Circulation<\/i> 2019; 140: 16\u201326, doi:10.1161\/circulationaha.118.038169.","DOI":"10.1161\/CIRCULATIONAHA.118.038169"},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Ruberg FL, Grogan M, Hanna M, Kelly JW, Maurer MS. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. <i>J Am Coll Cardiol<\/i> 2019; 73: 2872\u20132891, doi:10.1016\/j.jacc.2019.04.003.","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Kitaoka H, Izumi C, Izumiya Y, Inomata T, Ueda M, Kubo T, et al. JCS 2020 Guideline on diagnosis and treatment of cardiac amyloidosis. <i>Circ J<\/i> 2020; 84: 1610\u20131671, doi:10.1253\/circj.CJ-20-0110.","DOI":"10.1253\/circj.CJ-20-0110"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4. Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. <i>N Engl J Med<\/i> 2018; 379: 1007\u20131016, doi:10.1056\/nejmoa1805689.","DOI":"10.1056\/NEJMoa1805689"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Elliott P, Drachman BM, Gottlieb SS, Hoffman JE, Hummel SL, Lenihan DJ, et al. Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. <i>Circ Heart Fail<\/i> 2022; 15: e008193, doi:10.1161\/circheartfailure.120.008193.","DOI":"10.1161\/CIRCHEARTFAILURE.120.008193"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Damy T, Wang R, Maurer MS, Gillmore JD, Fontana M. Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage. <i>Eur J Heart Fail<\/i> 2025; 27: 2998\u20133009, doi:10.1002\/ejhf.3696.","DOI":"10.1002\/ejhf.3696"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Kuyama N, Izumiya Y, Takashio S, Usuku H, Tabira A, Oguni T, et al. Long-term effect of tafamidis on clinical parameters and prognostic predictors in patients with transthyretin amyloid cardiomyopathy. <i>Circ J<\/i> 2025; 89: 421\u2013431, doi:10.1253\/circj.CJ-24-0733.","DOI":"10.1253\/circj.CJ-24-0733"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Blatt PJ, Simpson T, Chen H, Masri A. National and regional Medicare spending on tafamidis, 2019\u20132021. <i>JAMA Netw Open<\/i> 2024; 7: e2426086, doi:10.1001\/jamanetworkopen.2024.26086.","DOI":"10.1001\/jamanetworkopen.2024.26086"},{"key":"9","doi-asserted-by":"publisher","unstructured":"9. Decker SRdR, Kazi DS. Tafamidis and the paradox of rare disease therapies. <i>JAMA Netw Open<\/i> 2024; 7: e2427219, doi:10.1001\/jamanetworkopen.2024.27219.","DOI":"10.1001\/jamanetworkopen.2024.27219"},{"key":"10","doi-asserted-by":"publisher","unstructured":"10. Kittleson MM, Ambardekar AV, Cheng RK, Griffin JM, Maurer MS, Nativi-Nicolau J, et al. Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance. <i>J Am Coll Cardiol<\/i> 2026; 87: 549\u2013565, doi:10.1016\/j.jacc.2025.09.004.","DOI":"10.1016\/j.jacc.2025.09.004"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Naito T, Nakamura K, Abe Y, Watanabe H, Sakuragi S, Katayama Y, et al. Prevalence of transthyretin amyloidosis among heart failure patients with preserved ejection fraction in Japan. <i>ESC Hear Fail<\/i> 2023; 10: 1896\u20131906, doi:10.1002\/ehf2.14364.","DOI":"10.1002\/ehf2.14364"},{"key":"12","doi-asserted-by":"publisher","unstructured":"12. Endo J, Tanzawa K, Sato Y, Watanabe H, Takashio S, Kubo T, et al. Patient characteristics and diagnosis of transthyretin amyloid cardiomyopathy in Japan baseline analysis of J-COSSA. <i>JACC Asia<\/i> 2026; 6: 1553\u20131566, doi:10.1016\/j.jacasi.2026.03.007.","DOI":"10.1016\/j.jacasi.2026.03.007"},{"key":"13","doi-asserted-by":"publisher","unstructured":"13. Kubota T, Kato S, Nagatomo D, Ishikita A, Nozoe M, Suematsu N. Real-world clinical impact of tafamidis on transthyretin amyloid cardiomyopathy: A decade of experience from a community-based hospital (2015\u20132024). <i>Circ Rep<\/i> 2025; 7: 442\u2013450, doi:10.1253\/circrep.CR-25-0031.","DOI":"10.1253\/circrep.CR-25-0031"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Kazi DS, Bellows BK, Baron SJ, Shen C, Cohen DJ, Spertus JA, et al. Cost-effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. <i>Circulation<\/i> 2020; 141: 1214\u20131224, doi:10.1161\/circulationaha.119.045093.","DOI":"10.1161\/CIRCULATIONAHA.119.045093"},{"key":"15","doi-asserted-by":"publisher","unstructured":"15. Gillmore JD, Damy T, Fontana M, Hutchinson M, Lachmann HJ, Martinez-Naharro A, et al. A new staging system for cardiac transthyretin amyloidosis. <i>Eur Heart J<\/i> 2018; 39: 2799\u20132806, doi:10.1093\/eurheartj\/ehx589.","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"16","doi-asserted-by":"publisher","unstructured":"16. Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: Reconstructing the data from published Kaplan\u2013Meier survival curves. <i>BMC Med Res Methodol<\/i> 2012; 12: 9, doi:10.1186\/1471-2288-12-9.","DOI":"10.1186\/1471-2288-12-9"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Uno H, Claggett B, Tian L, Fu H, Huang B, Kim DH, et al. Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis. <i>Ann Oncol<\/i> 2018; 29: 1092\u20131094, doi:10.1093\/annonc\/mdy109.","DOI":"10.1093\/annonc\/mdy109"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Perego C, Sbolli M, Specchia C, Fiuzat M, McCaw ZR, Metra M, et al. Utility of restricted mean survival time analysis for heart failure clinical trial evaluation and interpretation. <i>JACC Heart Fail<\/i> 2020; 8: 973\u2013983, doi:10.1016\/j.jchf.2020.07.005.","DOI":"10.1016\/j.jchf.2020.07.005"},{"key":"19","doi-asserted-by":"publisher","unstructured":"19. Dyer MTD, Goldsmith KA, Sharples LS, Buxton MJ. A review of health utilities using the EQ-5D in studies of cardiovascular disease. <i>Health Qual Life Outcomes<\/i> 2010; 8: 13, doi:10.1186\/1477-7525-8-13.","DOI":"10.1186\/1477-7525-8-13"},{"key":"20","unstructured":"20. Pichler F, Bray G. Around the world in HTAs: Japan \u2013 an algorithmic approach to containing costs. Office of Health Economics, 2026. https:\/\/www.ohe.org\/insights\/around-the-world-in-hta-japan-an-algorithmic-approach-to-containing-costs\/ (accessed May 8, 2026)."},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Royston P, Parmar MKB. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. <i>Stat Med<\/i> 2002; 21: 2175\u20132197, doi:10.1002\/sim.1203.","DOI":"10.1002\/sim.1203"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Hlatky MA. Willingness to pay for high-cost medications. <i>Circulation<\/i> 2020; 141: 1225\u20131226, doi:10.1161\/circulationaha.120.045966.","DOI":"10.1161\/CIRCULATIONAHA.120.045966"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol<\/i> 2022; 79: e263\u2013e421, doi:10.1016\/j.jacc.2021.12.012.","DOI":"10.1016\/j.jacc.2021.12.012"},{"key":"24","doi-asserted-by":"publisher","unstructured":"24. Kubota T. Geographical disparities in the detection and certification of systemic amyloidosis in Japan: A nationwide registry analysis, 2015\u20132024. <i>Circ Rep<\/i> 2026; 8: 1113\u20131120, doi:10.1253\/circrep.CR-26-0088.","DOI":"10.1253\/circrep.CR-26-0088"},{"key":"25","doi-asserted-by":"publisher","unstructured":"25. Endo J, Sano M, Izumiya Y, Tsujita K, Nakamura K, Tahara N, et al. A statement on the appropriate administration of tafamidis in patients with transthyretin cardiac amyloidosis. <i>Circ J<\/i> 2019; 84: 15\u201317, doi:10.1253\/circj.CJ-19-0811.","DOI":"10.1253\/circj.CJ-19-0811"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/11\/90_CJ-26-0576\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T03:23:54Z","timestamp":1792812234000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/90\/11\/90_CJ-26-0576\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,23]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-26-0576","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,23]]},"article-number":"CJ-26-0576"}}